← All Grace Therapeutics, INC filings

Grace Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
GRCE
Grace Therapeutics, INC
DEFA14A: Grace Therapeutics Files Definitive Proxy Materials
Grace Therapeutics, Inc. has filed definitive additional proxy materials with the SEC.
NASDAQ
GRCE
Grace Therapeutics, INC
DEF: Grace Therapeutics Schedules 2025 Annual Meeting, Seeks Shareholder Approval for Directors and Executive Compensation
Grace Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 12, 2025, seeking approval for director nominees, executive compensation, and auditor ratification.
NASDAQ
GRCE
Grace Therapeutics, INC
DEFA14A: Acasti Pharma Urges Shareholders to Vote Ahead of September 30th Annual Meeting
Acasti Pharma encourages shareholders to vote on key proposals, including director elections, auditor appointment, executive compensation, and corporate restructuring, before the upcoming Annual and Special Meeting on September 30, 2024.
NASDAQ
GRCE
Grace Therapeutics, INC
DEFA14A: Acasti Pharma Inc. Files Definitive Proxy Statement
Acasti Pharma Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.